The FDA has now approved AstraZeneca's convenient once-a-week glucose lowering drug for 10 to 17-year-olds with type 2 diabetes. In a pivotal trial, the Bydureon BCise injection significantly reduced blood sugar in the adolescents receiving the drug, as measured by HbA1c.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,